Best Migraine Prevention Medication: What to Know

Who should consider migraine prevention?

Preventive treatment is generally recommended when migraines are frequent enough, severe enough, or disabling enough that treating each attack individually is not sufficient. Common thresholds include four or more migraine days per month, migraines that significantly impair work or daily life, or attacks that do not respond well to acute medications. Preventive therapy reduces attack frequency, severity, and the amount of acute medication needed.

What are the older (traditional) preventive medications?

Several drug classes with good evidence for migraine prevention have been used for decades 1Ref 1Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012).Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.Evidence base for traditional preventive medications including beta-blockers, antiepileptics, and tricyclics:

Beta-blockers — propranolol and metoprolol are among the most studied. They have the most evidence and are often tried first in people without contraindications such as asthma or severe depression.

Antiepileptic drugs — topiramate and valproate have strong evidence for migraine prevention. Topiramate is commonly used but can affect word-finding and is not appropriate during pregnancy. Valproate is also contraindicated in pregnancy.

Tricyclic antidepressants — amitriptyline has evidence for prevention and also addresses comorbid insomnia; nortriptyline is better tolerated in some people.

Other antidepressants — venlafaxine has supporting evidence and may suit people who also have anxiety or depression.

Calcium channel blockers — verapamil is used in some patients, particularly those with certain migraine subtypes.

All of these are taken daily and typically require six to eight weeks at the target dose before the benefit becomes apparent.

What are CGRP-targeting therapies, and how do they differ?

Calcitonin gene-related peptide (CGRP) plays a central role in migraine pain signaling. A new class of treatments specifically targets CGRP or its receptor:

CGRP monoclonal antibodies (monthly or quarterly injections) — erenumab, fremanezumab, galcanezumab, and eptinezumab all reduce migraine frequency with a convenient injection schedule (monthly for most, quarterly for fremanezumab and eptinezumab). They have a favorable side-effect profile and begin working faster than older daily pills — sometimes within weeks 2Ref 2Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society (2021).The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.Integration of CGRP-targeting therapies into migraine treatment algorithms3Ref 3Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society (2024).Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.CGRP-targeting therapies positioned as first-line prevention options.

CGRP receptor antagonists (gepants) for prevention — atogepant and rimegepant are oral daily or every-other-day options that block the CGRP receptor and have evidence for both prevention and acute treatment.

The American Headache Society now positions CGRP-targeting therapies as a first-line option for prevention, not just a reserve for people who have failed multiple older drugs 3Ref 3Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society (2024).Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.CGRP-targeting therapies positioned as first-line prevention options. They are particularly useful when older medications are not tolerated or when rapid response is a priority.

Practical considerations: CGRP antibodies require injection (self-administered with an auto-injector) or infusion; they are significantly more expensive than generic older medications and may require prior authorization from insurance.

How do I work with my clinician to choose the right one?

A clinician will consider several factors when recommending a preventive medication:

• Comorbid conditions — depression or anxiety may favor amitriptyline or venlafaxine; high blood pressure may favor a beta-blocker or verapamil; epilepsy may favor topiramate or valproate.
• Pregnancy and reproductive plans — valproate and topiramate are not safe in pregnancy; CGRP antibody use in pregnancy is not yet well-studied.
• History of cardiovascular disease — some beta-blockers are contraindicated; CGRP antibodies may require caution in people with a recent cardiovascular event.
• Your tolerance for side effects — drowsiness (amitriptyline), cognitive effects (topiramate), and weight changes vary by medication.
• Prior medication trials — if several older options have failed, moving to a CGRP therapy is a reasonable next step.

Keeping a headache diary before your appointment — tracking dates, duration, severity, triggers, and any medications used — gives your clinician the clearest picture of your pattern and helps measure response to treatment.

A Gale primary care clinician can start the conversation, initiate first-line preventive therapy, and coordinate referral to a neurologist or headache specialist for complex cases or when CGRP therapy is being considered.

How long does it take to know if a prevention medication is working?

Traditional daily medications require at least two to three months at the target dose before a meaningful evaluation. CGRP monoclonal antibodies may show benefit within the first four weeks. It is common to try more than one medication before finding the best fit. Stopping a preventive medication abruptly — especially beta-blockers or tricyclics — should be done under clinician guidance to avoid rebound or withdrawal effects.